But new research suggests that a simple blood test may be able to predict osteoporosis risk, allowing doctors to intervene ...

Nearly one-quarter of adults with metabolic dysfunction-associated steatotic liver disease and cirrhosis presented before age ...

Living to 100 is no longer an abstract rarity, yet it remains uncommon enough to raise a persistent question. Do people who ...

An oral pyruvate kinase (PK) activator, mitapivat becomes the only approved option for treating anemia in both ...

Routine blood tests are increasingly detecting elevated liver enzymes, which may signal liver stress or damage. While mild ...

Patients should be selected for treatment with Enhertu in combination with pertuzumab based on confirmed HER2-positive status or HER2 gene amplification (IHC 3+ or ISH+).

Akeega combines niraparib, a PARP inhibitor, and abiraterone acetate, a CYP17 inhibitor, into a single tablet for BRCA2-mutated mCSPC.

AQVESME is the only FDA-approved medicine for anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemiaMarketed under AQVESME brand name in the U.S. for thalassemia ...

EMA provided overall agreement with the proposed Phase 3 clinical trial of VCN-01 in combination with ...

Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that Revuforj ® (revumenib) was named Best New Drug at the ...